Ashok Kumar Thinks Commercial Conversion Should Establish the Next Year of Growth for DarioHealth
Research Report
ThinkEquity Morning Briefing | 10-23-2026| Stocks Find Their Feet After AI Trades 180
ThinkEquity Morning Briefing | 10-22-2026| Oil Jolt Raises Stakes as Tech Tests the Floor
Unusual Machines Closes Upgrade Energy Deal, Completing US-Made Drone Powertrain
Red Cat Bets on Low-Cost TRICHON Drone as It Unifies Brands at AUSA
Drone Maker Powerus Goes Public on Nasdaq With Unusual Machines as a Backer
Greenland Oil Drilling Moves Closer After Government-Approved Environmental Work
Unusual Machines Invests in Draganfly as Counter-Drone Market Eyes Tripling by 2030
Unusual Machines Inc. (UMAC:NYSE American) commits to a strategic investment in Draganfly Inc. (DPRO:CSE; DPRO:NASDAQ; 3U8:FSE), while a sector report highlights UMAC amid counter-drone spending surge to US$55 billion-plus by 2034.Red Cat Holdings Eyes $150M-$180M Revenue in AI Drone Surge
Red Cat Holdings (RCAT) targets $150M-$180M in 2026 revenue amid surging AI drone defense spending, backed by manufacturing scale and analyst buy ratings up to $20.Drone Maker Rides Explosive US Defense-Tech Boom
Red Cat Holdings Inc. (RCAT:NASDAQ) is expanding its manufacturing footprint and product lineup as U.S. defense spending shifts toward AI-driven autonomy. Find out why one analyst sees multiple growth avenues opening for the company in the second half of 2026.Ashok Kumar Thinks Permits and Funding Need to Unlock the Basin Value for Greenland Energy
Research Report
Progress against Greenland Energy's milestones could improve recognition of the basins exploration potential. Drone Component Maker Boosts XTEND Investment to $27.5M
Unusual Machines commits another $20 million to XTEND AI Robotics, lifting its total stake to $27.5 million as part of a larger financing round tied to the NYSE listing.Drone Component Maker Boosts Stake in AI Robotics Leader
Unusual Machines Inc. (UMAC:NYSEAMERICAN) raises its stake in newly NYSE-listed XTEND AI Robotics. Find out why one analyst says the investment story has shifted from financing worries to manufacturing execution.Ashok Kumar Thinks Full Enrollment Brings the Pivotal Readout Into View for Annovis Bio
Research Report
The path for Annovis Bio includes financing, persuasive cognition and function, balanced safety, a workable FDA filing path, and durable exclusivity. Ashok Kumar Thinks Cash Sets the Floor, Orders Set the Target for Sidus Space
Research Report
Funded commercialization could build a more valuable business to Sidus Space. 
Key Charts
